James E. Langston’s practice focuses on public and private merger and acquisition transactions.

Jim also provides advice regarding governance matters and the fiduciary duties of officers and directors to companies and their boards. 

In 2016, Law360 named Jim one of its “Rising Stars” for his work on some of the largest and most high-profile M&A transactions in recent years. Jim was also named a Next Generation M&A Lawyer by Legal 500 U.S.

Jim joined the firm in 2011 and became a partner in 2015.

Notable Experience

  • The special committee of the Spectrum Brands board of directors in connection with HRG Group’s (the 58% stockholder of Spectrum Brands) proposal to combine HRG and Spectrum Brands

  • Songa Offshore in its pending $3.8 billion combination with Transocean.

  • RCN Communications in its $2.3 billion acquisition of Wave Broadband.

  • Allergan in its announced $160 billion merger with Pfizer, $40.5 billion sale of its global generics pharmaceuticals business to Teva and $2.1 billion acquisition of Kythera Biopharmaceuticals.

  • Actavis in its $70 billion white knight acquisition of Allergan.

  • Suntory Holdings in its $16 billion acquisition of Beam.

  • Westlake Chemical Corporation in its unsolicited proposal to acquire Axiall Corporation and related proxy contest and the resulting $3.8 billion negotiated acquisition.

  • Surgical Care Affiliates in its $2.5 billion sale to OptumCare.

  • TPG Capital in various transactions, including its investment in Creative Artists Agency; $2.25 billion acquisition of RCN Telecommunications and Grande Communications; recapitalization of RentPath, including the sale of a significant equity stake to Providence Equity Partners; $1.7 billion acquisition of Savers; and $525 million acquisition of Primedia.

  • Warburg Pincus in numerous matters, including its acquisitions of Universal Services of America, Wencor Group, Gabriel Brothers Inc. and Duravant.

  • GlaxoSmithKline in its unsolicited tender offer to acquire Human Genome Sciences and the resulting $3.6 billion negotiated acquisition.

  • Biomet and its private equity consortium owners — Blackstone, Goldman Sachs PIA, KKR and TPG — in Biomet’s $13.35 billion cash and stock merger with Zimmer Holdings; and in its acquisition of the global trauma business of DePuy Orthopaedics.

  • Bausch + Lomb and Warburg Pincus in the $8.7 billion sale of Bausch + Lomb to Valeant Pharmaceuticals.

  • Neiman Marcus, TPG Capital and Warburg Pincus in the $6 billion sale of Neiman Marcus to Ares Management and CPPIB.

  • Lafarge in various divestitures in connection with its €40 billion merger of equals with Holcim.

  • Medtronic in its $49.9 billion acquisition of Covidien.

  • Acadia Healthcare Company in its $1.2 billion acquisition of CRC Health Group.

  • Danfoss A/S in its take-private of Sauer-Danfoss.

  • Conversus Capital L.P. in the $1.4 billion sale of its portfolio of PE fund interests to an affiliate of HarbourVest Partners LLC.

  • GT Nexus in its $675 million acquisition by Infor.

  • Universal Services of America in numerous matters, including its merger of equals with Allied Barton and $131 million acquisition of the security business of ABM.

  • Bank of America Merrill Lynch, Barclays, Citigroup, Goldman Sachs, JPMorgan, Lazard and Morgan Stanley as financial advisors in various M&A transaction.


See More


Assessing Financial Advisor Compensation Disclosure Following Vento v. CurryCleary M&A and Corporate Governance Watch Blog (April 10, 2017)